{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:03:53Z","timestamp":1768453433082,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijantimicag.2022.106636","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T02:01:43Z","timestamp":1657332103000},"page":"106636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of pre\u2010existent drug resistance on virological efficacy of single\u2010tablet regimens in people living with HIV"],"prefix":"10.1016","volume":"60","author":[{"given":"Giulia","family":"Stella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-8768","authenticated-orcid":false,"given":"Lorenzo","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico Di","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-2960","authenticated-orcid":false,"given":"Ilaria","family":"Vicenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Celani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Paola","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-8346","authenticated-orcid":false,"given":"Francesca","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0858","authenticated-orcid":false,"given":"Lorenzo","family":"Piermatteo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9921-3684","authenticated-orcid":false,"given":"Antonia","family":"Bezenchek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1114","authenticated-orcid":false,"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106636_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US Medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1060028018793252","article-title":"HIV Clinical Updates: New single-tablet regimens","volume":"53","author":"Sebaaly","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0003","first-page":"242","article-title":"Single-versus multiple-tablet HIV regimens: adherence and hospitalization risk","volume":"22","author":"Sutton","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/09540121.2018.1442554","article-title":"Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment na\u00efve patients","volume":"30","author":"Hemmige","year":"2018","journal-title":"AIDS Care"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0005","unstructured":"European AIDS Clinical Society (EACS). EACS guidelines, version 10.1. Updated October 2020. https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html [accessed 11 April 2021 ]."},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0006","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services (DHHS). Updated 24 February 2021. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/archive\/AdultandAdolescentGL_2021_08_16.pdf [accessed 11 April 2021]."},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1179\/1528433614Z.0000000009","article-title":"96-Week resistance analyses of the STaR study: rilpivirine\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-na\u00efve, HIV-1-infected subjects","volume":"16","author":"Porter","year":"2015","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/15284336.2015.1115585","article-title":"Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate in the SPIRIT study","volume":"17","author":"Porter","year":"2016","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcv.2018.03.012","article-title":"Rare emergence of drug resistance in HIV-1 treatment-na\u00efve patients receiving elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide for 144 weeks","volume":"103","author":"Margot","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0010","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0011","series-title":"17th European Meeting on HIV & Hepatitis\u2014Treatment strategies & antiviral drug resistance; 22\u201324 May 2019; Rome, Italy. Reviews in Antiviral Therapy and Infectious Diseases","article-title":"Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study","author":"Rossetti","year":"2019"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0012","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/sim.3623","article-title":"The estimation of average hazard ratios by weighted Cox regression","volume":"28","author":"Schemper","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0013","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0014","first-page":"855","article-title":"Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir\/emtricitabine\/rilpivirine single-tablet regimen","volume":"72","author":"Armenia","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0015","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1093\/jac\/dku294","article-title":"Initiation of rilpivirine, tenofovir and emtricitabine (RPV\/TDF\/FTC) regimen in 363 patients with virological vigilance assessment in \u2018real life","volume":"69","author":"Amiel","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0016","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/1060028019896638","article-title":"Effectiveness, safety, and costs of dolutegravir\/abacavir\/lamivudine single-tablet regimen in a real-life cohort of HIV-1 adult infected patients","volume":"54","author":"Rodriguez-Gonzalez","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0017","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0018","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jac\/dkaa019","article-title":"M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients","volume":"75","author":"Jary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0019","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3851\/IMP2531","article-title":"Impact of pre-therapy viral load on virological response to modern first-line HAART","volume":"18","author":"Santoro","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3851\/IMP3309","article-title":"Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen","volume":"24","author":"Armenia","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0021","doi-asserted-by":"crossref","first-page":"e2134","DOI":"10.1093\/cid\/ciaa1614","article-title":"Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatment","volume":"73","author":"Pyngottu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/hiv.12956","article-title":"Transmitted drug resistance to NRTIs and risk of virological failure in na\u00efve patients treated with integrase inhibitors","volume":"22","author":"Borghetti","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcv.2011.09.018","article-title":"CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy","volume":"53","author":"Boulassel","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0024","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/09540121.2017.1391984","article-title":"Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach","volume":"30","author":"de Vasconcellos Carvalhaes de Oliveira","year":"2018","journal-title":"AIDS Care"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S2055-6640(20)30037-6","article-title":"Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz\u00a0+\u00a0tenofovir\u00a0+\u00a0emtricitabine for HIV","volume":"5","author":"Stirrup","year":"2019","journal-title":"J Virus Erad"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0026","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dkv205","article-title":"Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences","volume":"70","author":"Santos","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0027","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12879-020-4837-y","article-title":"Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0028","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0029","first-page":"2197","article-title":"Evolution of the K65R, K103N and M184V\/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010","volume":"68","author":"Charpentier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0030","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1038\/s41598-018-21081-x","article-title":"Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009\u20132016: a nationwide study","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0031","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1097\/01.aids.0000186828.99032.60","article-title":"Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance","volume":"19","author":"Tariq Sadiq","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.aids.0000199825.34241.49","article-title":"Adherence\u2013resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness","volume":"20","author":"Bangsberg","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106636_bib0033","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922001480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:39Z","timestamp":1760377479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0924857922001480"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106636","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of pre\u2010existent drug resistance on virological efficacy of single\u2010tablet regimens in people living with HIV","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106636"}}